LBRXHealthcare · BiotechnologyThe 11 Wall Street analysts covering LB Pharmaceuticals, Inc. hold a median 12-month price target of $55 — +39.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 21 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores LB Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (69): The shares have been drifting up relative to others.
Growth (16): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LBRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +39.5% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Oct 2026 | Canaccord Genuity | Initiates | Buy | $65 |
| 6 Oct 2026 | Guggenheim | Initiates | Buy | $80 |
| 5 Oct 2026 | Roth Capital | Downgrade | Neutral | $37 → $35 |
| 2 Oct 2026 | Needham | Initiates | Buy | $68 |
| 24 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $45 → $60 |
| 24 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Aug 2026 | BMO Capital | Maintains | Outperform | — |
| 12 Aug 2026 | BMO Capital | Maintains | Outperform | $46 → $54 |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $45 |
| 21 July 2026 | BMO Capital | Initiates | Outperform | $46 |
| 21 July 2026 | BMO Capital | Initiates | Outperform | — |
| 7 July 2026 | Wolfe Research | Initiates | Outperform | $45 |
| 7 July 2026 | Wolfe Research | Initiates | Outperform | — |
| 27 Apr 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 10 Apr 2026 | Craig-Hallum | Initiates | Buy | — |
| 27 Mar 2026 | Stifel | Maintains | Buy | — |
| 11 Dec 2025 | Stifel | Maintains | Buy | — |
| 6 Oct 2025 | Leerink Partners | Initiates | Outperform | — |
| 6 Oct 2025 | Piper Sandler | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LBRX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, LB Pharmaceuticals, Inc. returned +150.9% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 2% of US stocks
Cheaper than 26% of US stocks
Cheaper than 86% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
LB Pharmaceuticals, Inc. has a market value of $1.3B and an enterprise value of $1.0B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$85.7M.
Diluted earnings per share, trailing twelve months: $−3.44.
Free cash flow in the twelve months to 30 June 2026: −$82.8M.
Trailing P/E: 410.0×; forward P/E: −8.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
LB Pharmaceuticals, Inc. employs 49 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own LB Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
LB Pharmaceuticals announced that members of its executive team will present and participate in upcoming investor conferences.
Why it matters — LBRX watchers may note the scheduled investor-event appearances as an opportunity for the company to communicate with investors.
LB Pharmaceuticals announced it will host an in-person and virtual R&D Day on October 27, 2026, beginning at 2:00 p.m. ET, with a reception to follow. The event will focus on advancing LB-102, with a focus on schizophrenia treatment.
Why it matters — LBRX watchers may follow the event for company presentations about its research and development priorities for LB-102.
Seeking Alpha assigns LB Pharmaceuticals a buy rating with a base-case valuation of $85 per share and potential upside to $150 if Phase 3 trials and clinical differentiation succeed. The article highlights LB-102's N-methyl modification, which enables brain receptor occupancy at lower doses than amisulpride, though the clinical benefit of the R-enantiomer's 5-HT7 activity remains unproven.
Why it matters — LBRX watchers would care because the piece outlines LB-102's differentiation potential and its Phase 3 and clinical-outcome milestones as key factors in the drug's valuation.
LB Pharmaceuticals, Inc. announced the appointment of Susan G. Kozauer, M.D. to the company, as disclosed in a Sept. 15, 2026 GlobeNewsWire release. The announcement focuses on the new appointment of the neuromedicines company.
Why it matters — A LBRX watcher would care because management appointments can signal strategic direction and strengthen the leadership of the company developing treatments for underserved brain disorders.
LB Pharmaceuticals, an IPO stock, has more than tripled in value in under a year as investors follow its work in neuropsychiatric disorders. The article questions whether the company could become a takeover target.
Why it matters — LBRX watchers would care because the stock's rapid rise and its progress in neuropsychiatric disorders could draw acquisition interest.
The 11 Wall Street analysts covering LB Pharmaceuticals, Inc. have a median 12-month price target of $55, with estimates ranging from $35 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering LB Pharmaceuticals, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LB Pharmaceuticals, Inc. 14 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Oct 2026, LB Pharmaceuticals, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (69 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +39.5% from the last close, and Ticker Nerd's factor model ranks LB Pharmaceuticals, Inc. 14 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering LB Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $80 over the next 12 months.
LB Pharmaceuticals, Inc. returned +150.9% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases.
The most recent item we track (GlobeNewsWire, 15 Oct 2026): "LB Pharmaceuticals to Participate in Upcoming Investor Events". LB Pharmaceuticals announced that members of its executive team will present and participate in upcoming investor conferences.
LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead program, LB-102, is an oral small-molecule candidate being advanced for acute schizophrenia and studied across additional psychiatric indications, including bipolar I depression and major depressive disorder. The company’s work centers on central nervous system medicines designed to address unmet needs in severe mental health disorders, with an emphasis on improving treatment options through differentiated pharmacology. LB Pharmaceuticals Inc. operates as a specialized drug developer within the healthcare sector and focuses on moving its pipeline through clinical development toward potential commercialization.
CEO Ms. Heather D. Turner Esq., J.D. · 49 employees · United States · https://lbpharma.us
